KNSA
Kiniksa Pharmaceuticals, Ltd.
KNSA's fundamentals are strong: revenue grew 58% and its operating margin rose 7 points to 14%. At 74x earnings, it's trading in line with its usual 69x. Analysts expect that strong growth to continue, though they disagree widely on how much.
KNSA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Healthy |
KNSA's revenue, profitability, cash flow and balance sheet are all currently healthy.
KNSA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.2x | $6.87 | -93% |
| Forward | 63x | $96.28 | — |
| Fair | 67x | $87.85 | -8.8% |
| Current | 74x | $96.28 | — |
| Expensive | 143x | $188 | +95% |
Historical ranges are pointers, not guarantees.
KNSA's PE is in its fair range at 74x. If earnings grow as analysts expect, today's price would be 63x next year's earnings.
KNSA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for KNSA, but weaker profitability. However, they disagree widely on these estimates.
KNSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.52 | +16% |
| Q3 2026 | $1.31 | +185% |
| Q2 2026 | $0.98 | +1860% |
| Q1 2026 | $0.91 | +$1.15 |
| Q4 2025 | $0.75 | +$1.35 |
| Q3 2025 | $0.46 | +$0.58 |
| Q2 2025 | $0.05 | +$0.19 |
| Q1 2025 | -$0.24 | -285% |
| Q4 2024 | -$0.60 | -400% |
KNSA's earnings per share have fallen from their peak: $1.31 over the past year, against $3.28 in mid-2023.
KNSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $286M | +58% |
| Q2 2026 | $243.6M | +55% |
| Q1 2026 | $214.3M | +56% |
| Q4 2025 | $202.1M | +65% |
| Q3 2025 | $180.9M | +61% |
| Q2 2025 | $156.8M | +44% |
| Q1 2025 | $137.8M | +73% |
| Q4 2024 | $122.5M | +47% |
KNSA's revenue has grown year over year for 12 quarters in a row: $286M last quarter, up 58% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +5.7 points |
| Q2 2026 | 11% | -1.7 points |
| Q1 2026 | 14% | +4 points |
| Q4 2025 | 9.8% | +26 points |
| Q3 2025 | 13% | +22 points |
| Q2 2025 | 13% | +13 points |
| Q1 2025 | 9.6% | +30 points |
| Q4 2024 | -16% | -16 points |
KNSA's operating margin was 19% last quarter, up 5.7 points from the same quarter a year ago, near the top of its range since 2021.
KNSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $47.4M | +44% |
| Q2 2026 | $46.5M | +67% |
| Q1 2026 | $50M | +125% |
| Q4 2025 | $53.3M | +187% |
| Q3 2025 | $33M | +$35.2M |
| Q2 2025 | $27.9M | +440% |
| Q1 2025 | $22.2M | +469% |
| Q4 2024 | $18.6M | +335% |
KNSA generated $197M in free cash flow over the past year, up 94% from the year before.
KNSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +1.5M shares |
| 1 year | +6.1% | +4.9M shares |
| 3 years | +21% | +14.7M shares |
| 5 years | +24% | +16.3M shares |
| Available history | +57% | +30.9M shares |
KNSA has 85M diluted shares, up 6.1% from a year ago.
KNSA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -4.4x | Net Cash |
| Q2 2025 | -32.1x | Net Cash |
| Q2 2023 | -2.8x | Net Cash |
| Q1 2023 | -3.3x | Net Cash |
KNSA has more cash than debt.
KNSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 79.8 | Overbought |
| Stochastic | 85.1 | Overbought |
KNSA's weekly RSI is 80 (overbought) and its Stochastic is 85 (overbought).
KNSA PE vs Healthcare Sector
| Metric | KNSA | Sector median | Relative |
|---|---|---|---|
| PE | 74x | 26x | 184% above |
| PE % | 54 | 29 | 25 pts above |
KNSA is trading at 74x earnings, a 184% premium to the Healthcare sector's median of 26x.
KNSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $83.5 | 15% above |
| 20 week MA | $76.9 | 25% above |
| 50 week MA | $59.0 | 63% above |
| 100 week MA | $43.7 | 121% above |
| 200 week MA | $30.9 | 211% above |
KNSA is in an uptrend: it's above all five of its weekly moving averages, and 211% above its 200-week average.
KNSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.7 | $19.0 | +62% |
| 2021 | $19.0 | $13.1 | -31% |
| 2022 | $13.1 | $15.5 | +18% |
| 2023 | $15.5 | $17.5 | +13% |
| 2024 | $17.5 | $20.0 | +14% |
| 2025 | $20.0 | $42.0 | +110% |
| 2026 YTD | $42.0 | $96.3 | +129% |
KNSA has finished higher in five of the last six years, two of them by more than 50%. It's up 129% so far in 2026.